1. Home
  2. SLS
  3. SLS News

Latest SELLAS Life Sciences Group Inc. (SLS) News on February 23, 2025

Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment
SLS

Clinical Trials Arena

2 days ago

Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL
SLS

GlobeNewswire

3 days ago

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
SLS

GlobeNewswire

25 days ago

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SLS

MT Newswires

a month ago

SELLAS Life Sciences Shares Fall; Interim Trial Results on Acute Myeloid Leukemia Treatment Issued

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
SLS

GlobeNewswire

a month ago

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

SELLAS Announces Key Business Objectives for 2025
SLS

GlobeNewswire

a month ago

SELLAS Announces Key Business Objectives for 2025

SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET
SLS

GlobeNewswire

2 months ago

SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
SLS

GlobeNewswire

2 months ago

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML
SLS

GlobeNewswire

2 months ago

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML

SELLAS announces data indicating key predictor of response to SLS009 in solid cancers
SLS

Clinical Trials Arena

3 months ago

SELLAS announces data indicating key predictor of response to SLS009 in solid cancers

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers
SLS

GlobeNewswire

3 months ago

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

We're A Little Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn Rate
SLS

Simply Wall St.

3 months ago

We're A Little Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn Rate

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update
SLS

GlobeNewswire

3 months ago

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024
SLS

GlobeNewswire

4 months ago

SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

SLS

MT Newswires

4 months ago

SELLAS Life Sciences Gets FDA Rare Pediatric Disease Designation for Acute Myeloid Leukemia Immunotherapy

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia
SLS

GlobeNewswire

4 months ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
SLS

GlobeNewswire

4 months ago

SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Sellas Life Sciences Group Inc (NASDAQ:SLS): A Bull Case Theory
SLS

Insider Monkey

5 months ago

Sellas Life Sciences Group Inc (NASDAQ:SLS): A Bull Case Theory

SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update
SLS

GlobeNewswire

6 months ago

SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update

SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
SLS

GlobeNewswire

7 months ago

SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market
SLS

GlobeNewswire

7 months ago

SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market

SLS

MT Newswires

7 months ago

Sellas Life Sciences' Potential Leukemia Treatment Receives Second Rare Pediatric Disease Designation

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia
SLS

GlobeNewswire

7 months ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia

SLS

MT Newswires

7 months ago

Sellas Life Sciences' Potential Myeloid Leukemia Therapy Receives EU Orphan Drug Designation

SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia
SLS

GlobeNewswire

7 months ago

SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia
SLS

GlobeNewswire

8 months ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia
SLS

GlobeNewswire

8 months ago

SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia

SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML
SLS

GlobeNewswire

8 months ago

SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML

Can SELLAS Life Sciences Group (NASDAQ:SLS) Afford To Invest In Growth?
SLS

Simply Wall St.

9 months ago

Can SELLAS Life Sciences Group (NASDAQ:SLS) Afford To Invest In Growth?

SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update
SLS

GlobeNewswire

9 months ago

SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level
SLS

GlobeNewswire

10 months ago

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study
SLS

GlobeNewswire

10 months ago

SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
SLS

GlobeNewswire

a year ago

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
SLS

GlobeNewswire

a year ago

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
SLS

GlobeNewswire

a year ago

SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
SLS

GlobeNewswire

a year ago

SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
SLS

GlobeNewswire

a year ago

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
SLS

GlobeNewswire

a year ago

SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference
SLS

GlobeNewswire

a year ago

SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time
SLS

GlobeNewswire

a year ago

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time

SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget
SLS

GlobeNewswire

a year ago

SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget

SLS

Associated Press Finance

a year ago

First Capital: Q4 Earnings Snapshot

SLS

GlobeNewswire

a year ago

First Capital, Inc. Reports Annual And Quarterly Earnings

Phoenix Motor Inc. Announces Pricing of $4.8 Million Registered Direct Offering
SLS

ACCESSWIRE

a year ago

Phoenix Motor Inc. Announces Pricing of $4.8 Million Registered Direct Offering

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024
SLS

GlobeNewswire

a year ago

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference
SLS

GlobeNewswire

a year ago

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference

Lantronix Appoints Christa Steele to Its Board of Directors
SLS

GlobeNewswire

a year ago

Lantronix Appoints Christa Steele to Its Board of Directors

Meta Materials Announces 1-for-100 Reverse Stock Split to Regain Nasdaq Compliance
SLS

ACCESSWIRE

a year ago

Meta Materials Announces 1-for-100 Reverse Stock Split to Regain Nasdaq Compliance

Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why
SLS

Zacks

a year ago

Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why

Bionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications
SLS

GlobeNewswire

a year ago

Bionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications

First Capital (NASDAQ:FCAP) shareholders have endured a 43% loss from investing in the stock three years ago
SLS

Simply Wall St.

a year ago

First Capital (NASDAQ:FCAP) shareholders have endured a 43% loss from investing in the stock three years ago

Home Federal Bancorp, Inc. of Louisiana Declares Quarterly Cash Dividend
SLS

GlobeNewswire

a year ago

Home Federal Bancorp, Inc. of Louisiana Declares Quarterly Cash Dividend

4 Stocks to Buy as Manufacturing Activity Makes Steady Progress
SLS

Zacks

a year ago

4 Stocks to Buy as Manufacturing Activity Makes Steady Progress

Sidoti Events, LLC's Virtual January Micro-Cap Conference
SLS

ACCESSWIRE

a year ago

Sidoti Events, LLC's Virtual January Micro-Cap Conference

Here's Why You Should Hold Zebra (ZBRA) in Your Portfolio
SLS

Zacks

a year ago

Here's Why You Should Hold Zebra (ZBRA) in Your Portfolio

16 Most Widely Held Stocks by Individuals
SLS

Insider Monkey

a year ago

16 Most Widely Held Stocks by Individuals

Intuitive Machines Enters into Warrant Exercise Transaction for $11.8 Million in Gross Proceeds
SLS

GlobeNewswire

a year ago

Intuitive Machines Enters into Warrant Exercise Transaction for $11.8 Million in Gross Proceeds

SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate
SLS

Zacks

a year ago

SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate

SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients
SLS

GlobeNewswire

a year ago

SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients

The 3 Best Penny Stocks to Buy in January 2024
SLS

InvestorPlace

a year ago

The 3 Best Penny Stocks to Buy in January 2024

Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization
SLS

Benzinga

a year ago

Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization

Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
SLS

Business Wire

a year ago

Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference

SLS

GlobeNewswire

a year ago

Aeries Technology to Participate at the 26th Annual ICR Conference

SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering
SLS

GlobeNewswire

a year ago

SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering

Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event
SLS

GlobeNewswire

a year ago

Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event

SELLAS Life Sciences Announces Proposed Public Offering
SLS

GlobeNewswire

a year ago

SELLAS Life Sciences Announces Proposed Public Offering

SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones
SLS

GlobeNewswire

a year ago

SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones

Analysts Expect Breakeven For Hall of Fame Resort & Entertainment Company (NASDAQ:HOFV) Before Long
SLS

Simply Wall St.

a year ago

Analysts Expect Breakeven For Hall of Fame Resort & Entertainment Company (NASDAQ:HOFV) Before Long

Web3 Winners: 3 Stocks to Invest in the Decentralized Web
SLS

InvestorPlace

a year ago

Web3 Winners: 3 Stocks to Invest in the Decentralized Web

Canadian Investment Regulatory Organization Trading Halt - DGHI
SLS

CNW Group

a year ago

Canadian Investment Regulatory Organization Trading Halt - DGHI

SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma
SLS

GlobeNewswire

a year ago

SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

Modiv Industrial, Inc.'s (NYSE:MDV) Path To Profitability
SLS

Simply Wall St.

a year ago

Modiv Industrial, Inc.'s (NYSE:MDV) Path To Profitability

How Did Aeries Technology, Inc's (NASDAQ:AERT) 13% ROE Fare Against The Industry?
SLS

Simply Wall St.

a year ago

How Did Aeries Technology, Inc's (NASDAQ:AERT) 13% ROE Fare Against The Industry?

SLS

GlobeNewswire

a year ago

Kanen Wealth Management Issues Letter To Real Good Food Company, Inc.’s Board of Directors

Despite Fast-paced Momentum, Invitae (NVTA) Is Still a Bargain Stock
SLS

Zacks

a year ago

Despite Fast-paced Momentum, Invitae (NVTA) Is Still a Bargain Stock

Linkage Global Inc Announces Closing of $6,000,000 Initial Public Offering
SLS

GlobeNewswire

a year ago

Linkage Global Inc Announces Closing of $6,000,000 Initial Public Offering

LeddarTech Becomes a Publicly Traded Company After Completing Business Combination with Prospector Capital Corp., Will Commence Trading on Nasdaq Under Ticker Symbol "LDTC"
SLS

PR Newswire

a year ago

LeddarTech Becomes a Publicly Traded Company After Completing Business Combination with Prospector Capital Corp., Will Commence Trading on Nasdaq Under Ticker Symbol "LDTC"

SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
SLS

GlobeNewswire

a year ago

SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

Is Advantage Solutions (ADV) Trading an Attractive Upside-To-Downside Ratio?
SLS

Insider Monkey

a year ago

Is Advantage Solutions (ADV) Trading an Attractive Upside-To-Downside Ratio?

Graphex Group Provides Important Updates on its Global Mine-to-Battery Solution, Including the Separation of its US Subsidiary Graphex Technologies LLC into a Standalone U.S. company, and Financing for a 200% Production Increase over Current Levels
SLS

Business Wire

a year ago

Graphex Group Provides Important Updates on its Global Mine-to-Battery Solution, Including the Separation of its US Subsidiary Graphex Technologies LLC into a Standalone U.S. company, and Financing for a 200% Production Increase over Current Levels

MDV or ESS: Which Is the Better Value Stock Right Now?
SLS

Zacks

a year ago

MDV or ESS: Which Is the Better Value Stock Right Now?

We Think Research Frontiers (NASDAQ:REFR) Needs To Drive Business Growth Carefully
SLS

Simply Wall St.

a year ago

We Think Research Frontiers (NASDAQ:REFR) Needs To Drive Business Growth Carefully

Real Good Foods Announces Expansion of its Nutritious Burritos into the Refrigerated Category in Club Stores Nationwide & Select Walmart Stores
SLS

GlobeNewswire

a year ago

Real Good Foods Announces Expansion of its Nutritious Burritos into the Refrigerated Category in Club Stores Nationwide & Select Walmart Stores

Vibe with STK Steakhouse and Kona Grill this Holiday Season with Craveable Menu Features and Cocktails that Give Back
SLS

Business Wire

a year ago

Vibe with STK Steakhouse and Kona Grill this Holiday Season with Craveable Menu Features and Cocktails that Give Back

Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism
SLS

GlobeNewswire

a year ago

Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism

Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023
SLS

GlobeNewswire

a year ago

Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023

DLH Holdings Corp. (NASDAQ:DLHC) Q4 2023 Earnings Call Transcript
SLS

Insider Monkey

a year ago

DLH Holdings Corp. (NASDAQ:DLHC) Q4 2023 Earnings Call Transcript

Easterly Government Properties Appoints Co-Founder Darrell Crate as CEO to Advance Mission-Critical Real Estate Strategy
SLS

Business Wire

a year ago

Easterly Government Properties Appoints Co-Founder Darrell Crate as CEO to Advance Mission-Critical Real Estate Strategy

GENERATIONS BANCORP NY, INC. APPOINTS ANGELA KREZMER AS PRESIDENT & CEO
SLS

PR Newswire

a year ago

GENERATIONS BANCORP NY, INC. APPOINTS ANGELA KREZMER AS PRESIDENT & CEO

Sidoti Events, LLC's Virtual December Small-Cap Conference
SLS

ACCESSWIRE

a year ago

Sidoti Events, LLC's Virtual December Small-Cap Conference

Synchronoss Technologies Board Appoints 180 Degree Capital’s Kevin Rendino as New Director
SLS

GlobeNewswire

a year ago

Synchronoss Technologies Board Appoints 180 Degree Capital’s Kevin Rendino as New Director

SLS

Business Wire

a year ago

Birks Group Reports Mid-Year Fiscal 2024 Results

3 Top-Rated Cannabis Stocks That Analysts Are Loving Now
SLS

InvestorPlace

a year ago

3 Top-Rated Cannabis Stocks That Analysts Are Loving Now

Penny Stock Powerhouses: 7 Picks Poised for Explosive Growth
SLS

InvestorPlace

a year ago

Penny Stock Powerhouses: 7 Picks Poised for Explosive Growth

Is Connect Biopharma Holdings (CNTB) Stock Outpacing Its Medical Peers This Year?
SLS

Zacks

a year ago

Is Connect Biopharma Holdings (CNTB) Stock Outpacing Its Medical Peers This Year?

Rubicon Awarded 2023 AWS Rising Star Partner of the Year Award
SLS

Business Wire

a year ago

Rubicon Awarded 2023 AWS Rising Star Partner of the Year Award

11 Best Cannabis Stocks To Buy Now
SLS

Insider Monkey

a year ago

11 Best Cannabis Stocks To Buy Now

The Trade That Backfired for America’s Biggest Wood-Pellet Exporter
SLS

The Wall Street Journal

a year ago

The Trade That Backfired for America’s Biggest Wood-Pellet Exporter

Zenvia Inc. (NASDAQ:ZENV) Q3 2023 Earnings Call Transcript
SLS

Insider Monkey

a year ago

Zenvia Inc. (NASDAQ:ZENV) Q3 2023 Earnings Call Transcript

Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial
SLS

GlobeNewswire

a year ago

Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

Share on Social Networks: